China Challenges the West in Stem-Cell Research
By Susan Brown,
The Chronicle of Higher Education
| 04. 10. 2007
In 1983, Sheng Huizhen did what many of China's brightest students do: She left to pursue research opportunities unavailable to her at home, first in Australia and then in the United States. Sixteen years later, in search of greater scientific freedom, she migrated again. This time she headed back to China. As a researcher who studies embryonic stem cells, Ms. Sheng found the climate in the United States limiting. Although she landed a postdoctoral fellowship at the National Institutes of Health, where she worked her way up to a permanent staff position, federal policy at the time barred her from using human embryos or the cells derived from them.
China, however, embraced Ms. Sheng's work. The city of Shanghai in 1999 offered her $875,000 to set up a new center at her alma mater, Shanghai Jiao Tong University, to study embryonic stem cells. She now directs a group of more than 50 people who are working on several lines of research, seeking to make cells useful for treating disease.
Restrictive policies and a frosty cultural climate in the United States...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
